stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
64.31
2.39
+3.86%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) EBITDA
Vaxcyte, Inc.'s EBITDA for fiscal 2025 was −$913.2M, compared with −$592.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.1B. Over the past ten years it has ranged from −$913.2M (fiscal 2025) to −$34.5M (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Vaxcyte, Inc. ranks 591st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$913.2M | — |
| FY2024 | −$592.4M | — |
| FY2023 | −$492.6M | — |
| FY2022 | −$223.8M | — |
| FY2021 | −$98.8M | — |
| FY2020 | −$88.2M | — |
| FY2019 | −$52.9M | — |
| FY2018 | −$34.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$298.0M | — |
| Mar 2026 | −$343.1M | — |
| Dec 2025 | −$267.2M | — |
| Sep 2025 | −$239.4M | — |
| 24 more quarters | Free account |
Against its own ten years
Low −$913.2M
High −$34.5M
Ten-year median
−$161.3M
Current reading's percentile
13
EBITDA against peers
| Company | EBITDA |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| PCVX Vaxcyte, Inc. | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item